ASH2023 abstracts: What’s hot in AML?

55

Saturday, Dec 9
09:30–09:45

Selinexor in combination with venetoclax and azacitidine for newly diagnosed (ND) unfit acute myeloid leukemia (AML): a multicenter, open-label prospective study

Li Yang

56

Saturday, Dec 9
09:45–10:00

Preliminary safety and efficacy of venetoclax and selinexor in combination with chemotherapy in pediatric and young adult patients with relapsed or refractory acute myeloid leukemia: Selclax

Sara Zarnegar-Lumley

57

Saturday, Dec 9
10:00–10:15

A first-in-human phase 1 study of the menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed/refractory acute leukemia harboring KMT2A or NPM1 alterations

Elias Jabbour

58

Saturday, Dec 9
10:15–10:30

Early results of the phase I/II study investigating the all-oral combination of the menin inhibitor revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax in acute myeloid leukemia (SAVE)

Ghayas C. Issa

59

Saturday, Dec 9
10:30–10:45

TIM-3 inhibitor sabatolimab for patients with acute myeloid leukemia (AML) with measurable residual disease (MRD) detected after allogeneic stem cell transplantation (AlloSCT): Preliminary findings from the phase Ib/II STIMULUS-AML2 study

Robert Zeiser

60

Saturday, Dec 9
10:45–11:00

Overcoming venetoclax (Ven) resistance through glutamine (Gln) depletion: Final analysis of the phase 1 trial of Ven and pegcrisantaspase (PegC) combination in relapsed and refractory (R/R) acute myeloid leukemia (AML)

Yuchen Liu

158

Saturday, Dec 9
14:15–14:30

Phase I/II study of quizartinib, venetoclax, and decitabine triple combination in FLT3-ITD mutated AML

Musa Yilmaz

159

Saturday, Dec 9
14:30–14:45

Final results of the phase Ib/II study evaluating enasidenib in combination with venetoclax in patients with IDH2-mutated relapsed/refractory myeloid malignancies

Guillaume Richard-Carpentier

160

Saturday, Dec 9
14:45–15:00

Venetoclax plus high-dose cytarabine and mitoxantrone (HAM-Ven) as salvage treatment for relapsed/refractory AML: updated results of the phase-I/II SAL Relax trial

Leo Ruhnke

162

Saturday, Dec 9
15:15–15:30

Tuspetinib myeloid kinase inhibitor safety and efficacy as monotherapy and combined with venetoclax in phase 1/2 trial of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML)

Naval Daver

218

Saturday, Dec 9
14:15–14:30

Naturally selected CD7-targeted chimeric antigen receptor (CAR)-T cell therapy for refractory/relapsed acute myeloid leukemia: phase I clinical trial

Peihua Lu

230

Saturday, Dec 9
14:15–14:30

Optimizing outcomes with myeloablative conditioning in older patients: Efficacy and safety of precision engineered Orca-T in patients > 55 years old with hematologic malignancies

Caspian H. Oliai

470

Sunday, Dec 10
09:45–10:00

Final results from phase 1 study of briquilimab, an anti-CD117 monoclonal antibody, in combination with low dose irradiation and fludarabine conditioning, shows durable remissions in older adults with acute myeloid leukemia in complete remission and myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation

Arpita Gandhi

471

Sunday, Dec 10
10:00–10:15

Mega-dose decitabine intensified regimen is more effective at eliminating pre-HSCT measurable residual disease compared to the Bu/Cy regimen: a multicenter prospective phase II study

Hao Zheng

474

Sunday, Dec 10
10:45–11:00

The modified melphalan-cladribine-busulfan-cyclophosphamide (MCBC) conditioning regimen improved relapse-free survival after allo-HSCT in refractory/relapsed AML

Xiaoyu Zhang

773

Monday, Dec 11
11:30–11:45

Safety and efficacy of Orca-Q with haploidentical donors for the treatment of advanced hematologic malignancies without the use of post-transplant cyclophosphamide

Samer A. Srour

771

Monday, Dec 11
11:00–11:15

CD33 CAR T-cells (CD33CART) for children and young adults with relapsed/refractory AML: dose-escalation results from a phase I/II multicenter trial

Nirali N. Shah

830

Monday, Dec 11
15:00–15:15

MRD directed treatment intensification with either FLAG-Ida or DA-Cladribine improves survival in older AML patients: results from the NCRI AML18 randomised trial

Nigel H. Russell

832

Monday, Dec 11
15:30–15:45

Quantum-First trial: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–specific measurable residual disease (MRD) clearance assessed through induction (IND) and consolidation (CONS) is associated with improved overall survival (OS) in newly diagnosed (nd) FLT3-ITD+ AML patients (pts)

Alexander Perl

833

Monday, Dec 11
15:45–16:00

A phase 2 study of the fully oral combination of ASTX727 (decitabine/cedazuridine) plus venetoclax for older and/or unfit patients with acute myeloid leukemia

Tapan M. Kadia

834

Monday, Dec 11
16:00–16:15

Venetoclax plus azacitidine, low dose cytarabine, aclarubicin and G-CSF (VA-CAG Regimen) for newly diagnosed young patients with acute myeloid leukemia: a prospective, multicenter, single-arm phase 2 clinical trial

Xiaoping Li

968

Monday, Dec 11
16:45–17:00

Phase Ib/2 study of oral decitabine/cedazuridine (ASTX727) and venetoclax in combination with the targeted mutant IDH1 inhibitor ivosidenib or the targeted mutant IDH2 inhibitor enasidenib: 2023 update

Himachandana Atluri

969

Monday, Dec 11
17:00–17:15

Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: updated results of a phase II trial

Xiaohui Suo

970

Monday, Dec 11
17:15–17:30

Comparing the efficacy and safety of venetoclax combined with decitabine versus conventional chemotherapy as induction therapy for young adults with newly diagnosed acute myeloid leukemia - interim analysis of a multicenter, randomized, phase 2b trial

Jing Lu

974

Monday, Dec 11
16:45–17:00

The FLT3-like gene expression signature predicts response to quizartinib in wild-type FLT3 acute myeloid leukemia: an analysis of the Pethema Quiwi trial

Adrian Mosquera Orgueira

1040

Monday, Dec 11
16:45–17:00

Infusion of UM171-expanded cord blood led to excellent survival in patients with high-risk leukemias: results from two independent phase II studies

Filippo Milano

2906

Sunday, Dec 10
18:00–20:00

Pivekimab sunirine (PVEK, IMGN632), a CD123-targeting antibody-drug conjugate, in combination with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukemia

Naval Daver

LBA-5

Tuesday, Dec 12
09:00–10:30

Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemia: topline efficacy and safety results from the Pivotal Augment-101 phase 2 study

Ibrahim Aldoss

263

Saturday, Dec 9
15:00–15:15

Alignment of later phase clinical trial eligibility criteria with drug safety in acute leukemia: minimizing unnecessary patient risk and exclusion

Thomas P. Walsh

469

Sunday, Dec 10
09:30–09:45

I-Apamistamab-led allogeneic hematopoietic cell transplant significantly improves overall survival in patients with TP53 mutated R/R AML

Hannah Choe

594

Sunday, Dec 10
17:45–18:00

Older adults with acute myeloid leukemia (AML) experience improvement in health-related quality of life (HRQoL) scores with intensive therapy: prospective study from ECOG-ACRIN (EA) E2906 phase 3 trial

James M. Foran

730

Monday, Dec 11
11:15–11:30

Outcomes for children with high risk acute myeloid leukemia on the MyeChild 01 international phase III clinical trial

Andrew Moore

732

Monday, Dec 11
11:45–12:00

Preferential efficacy of remission maintenance with HDC/IL-2 in age groups of patients with chemoresponsive or normal karyotype AML

Kristoffer Hellstrand

829

Monday, Dec 11
14:45–15:00

Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed AML based on the peripheral blast clearance rate: first result of the multicenter, randomized, phase 3 trial (RJ-AML 2016)

Yunxiang Zhang

918

Monday, Dec 11
16:00–16:15

Patient-reported outcomes in acute myeloid leukemia patients with FLT3-ITD mutation receiving quizartinib vs. standard chemotherapy: results from the Quantum-First trial

Esther Natalie Oliva

972

Monday, Dec 11
17:45–18:00

Quantum-First: Safety by treatment phase and by age in newly diagnosed (nd) patients (pts) with FMS-like tyrosine kinase 3–internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia (AML)

Harry P. Erba

973

Monday, Dec 11
16:30–16:45

Post-hoc analysis of measurable residual disease from BMT-CTN 1506/Morpho: FLT3-ITD variant allele frequency and survival are highly correlated

Mark J. Levis

1041

Monday, Dec 11
17:00–17:15

Haploidentical hematopoietic cell transplantation combined with an unrelated cord blood unit for adult acute myeloid leukemia results in improved survival compared to haploidentical hematopoietic cell transplantation: results of a multicenter, randomized, phase III trial

Biqi Zhou

1495

Saturday, Dec 9
17:30–19:30

Decider-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid (ATRA) or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy

Michael Lübbert

1582

Saturday, Dec 9
17:30–19:30

Clonal dynamics of gene mutations during oral azacitidine maintenance therapy in patients with acute myeloid leukemia (AML): outcomes from the QUAZAR AML-001 trial

Daniel Lopes De Menezes

4254

Monday, Dec 11
18:00–20:00

Kinetics of complete remission (CR) and CR duration and its impact on overall survival (OS) and event-free survival (EFS) in Quantum-First

Pau Montesinos

5097

Monday, Dec 11
18:00–20:00

The UK Impact Transplant Trials Network: An effective national strategy to accelerate the delivery of randomized trials in stem cell transplantation

Charles Craddock

62

Saturday, Dec 9
09:45–10:00

Machine learning provides individualized prediction of outcomes after first complete remission in adult AML patients - results from the Harmony Platform

Alberto Hernández Sánchez

161

Saturday, Dec 9
15:00–15:15

Acute myeloid leukemia patients who stopped venetoclax or/and azacytidine for other reasons than progression have a prolonged treatment free remission and overall survival: a Filo study

Sylvain Garciaz

236

Saturday, Dec 9
14:15–14:30

MMF is associated with worse OS in CMV seropositive AML patients undergoing MUD HCT with calcineurin-inhibitor-based GvHD prophylaxis

Rohtesh S. Mehta

261

Saturday, Dec 9
14:30–14:45

Age-related differences in utilization of allogeneic HCT for acute myeloid leukemia in California: results of a population-based, novel linked dataset

Christa L Meyer

421

Sunday, Dec 10
09:30–09:45

Molecular relapse after first-line intensive therapy in patients with core-binding factor and NPM1-mutated acute myeloid leukemia – a Filo study

Corentin Orvain

425

Sunday, Dec 10
10:30–10:45

The benefit of allogeneic transplant in 1st complete remission in NPM1 Mutated AML with or without FLT3 ITD is restricted to those testing MRD positive after induction – an analysis of the UK NCRI AML17 and AML19 studies

Jad Othman

550

Sunday, Dec 10
12:45–13:00

Intensive chemotherapy (IC) followed by oral azacitidine (AZA) maintenance versus venetoclax (VEN) plus AZA for patients (pts) with acute myeloid leukemia (AML): retrospective analysis of an Electronic Medical Record (EMR) database in the United States

Alice Mims

592

Sunday, Dec 10
17:15–17:30

Comparable survival of treatment Naïve TP53 mutated acute myeloid leukemia treated with hypomethylating agent compared to hypomethylating agent plus venetoclax based therapy

Talha Badar

657

Sunday, Dec 10
17:00–17:15

Pre-transplant somatic co-occurring mutations (by next generation sequencing) in acute myeloid leukemia: Frequency and impact on clinical outcomes after allogeneic hematopoietic cell transplantation - a large study on behalf of the EBMT Acute Leukemia Working Party

Ali Bazarbachi

658

Sunday, Dec 10
17:15–17:30

The impact of DNMT3A mutation on survival of AML patients receiving allogeneic hematopoietic cell transplantation in first remission depends on the karyotype and co-occurring mutations: on behalf of the EBMT Acute Leukemia Working Party

Iman Abou Dalle

659

Sunday, Dec 10
17:30–17:45

Comparative study for haplo, MSD and MUD allo-hcts for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Yishan Ye

896

Monday, Dec 11
15:00–15:15

How much have post-transplant outcomes improved since 2000 for older patients with acute myeloid leukemia? A study from the EBMT Acute Leukemia Working Party

Ali Bazarbachi

958

Monday, Dec 11
17:15–17:30

The shifting prognosis of FLT3 mutations in acute myeloid leukemia in the era of targeted therapy: A real-world study using large-scale electronic health record data

Matthew Schwede

967

Monday, Dec 11
16:30–16:45

Current results of intensive therapy in younger adults with acute myeloid leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 study on behalf of the Filo, ALFA, and SFGM-TC study groups

Hunault-Berger Mathilde

971

Monday, Dec 11
17:30–17:45

A comparison of acute myeloid leukemia (AML) regimens: Hypomethylating agents combined with ivosidenib or venetoclax in newly diagnosed patients with IDH1 mutations: a real-world evidence study

B. Douglas Smith

975

Monday, Dec 11
17:00–17:15

Fms-like tyrosine kinase 3 ligand kinetic profile is the strongest factor predicting refractoriness after induction and event-free survival in adults with AML: a Filo prospective multicentric study

Pierre Peterlin

977

Monday, Dec 11
17:30–17:45

Molecular ontogeny in AML is both prognostic and predictive in patients treated with hypomethylating agents plus venetoclax

Shai Shimony

1043

Monday, Dec 11
17:30–17:45

Comparing older matched related to younger matched unrelated donors in acute myeloid leukemia in remission using post-transplant cyclophosphamide

Simona Piemontese

1049

Monday, Dec 11
17:30–17:45

Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with relapsed/refractory secondary versus de novo AML: a study from the ALWP/EBMT

Arnon Nagler

61

Saturday, Dec 9
09:30–09:45

Modification of the ELN classification 2022 refines risk assessment in MDS/AML patients

Gregor Hoermann

819

Monday, Dec 11
15:15–15:30

Unraveling the impact of 2022 classifications on secondary acute myeloid leukemia: assessing the true qualification power of diagnostic qualifiers

Enrico Attardi

1566

Saturday, Dec 9
17:30–19:30

Advances in acute myeloid leukemia classification: A comparative analysis of Who-HAEM4R, Who-HAEM5, and International Consensus Classification

Xue Chen

376

Saturday, Dec 9
16:45–17:00

Frail and pre-frail older adults with acute myeloid leukemia have inferior survival due to higher rates of disease-related deaths

Ashley D. Hadjis

374

Saturday, Dec 9
16:15–16:30

Individual-level social determinants of health (SDOH) measures and treatment complications in acute leukemia

Eshana Shah

955

Monday, Dec 11
16:30–16:45

Evolving racial/ethnic disparities in AML survival in the novel therapy era: Real-world evidence of improved survival in older patients with the largest improvement in non-Hispanic Black patients

Xin Wang

424

Sunday, Dec 10
10:15–10:30

Measurable residual IDH2 before allogeneic transplant for acute myeloid leukemia

Gege Gui

721

Monday, Dec 11
10:30–10:45

Secondary-type mutations do not impact the favorable outcome of NPM1-mutated acute myeloid leukemia patients – results from a large cohort of intensively treated patients

Marius Bill

723

Monday, Dec 11
11:00–11:15

Mutational and cytogenetic dynamics at diagnosis and relapse in acute myeloid leukemia: influence of intensity and type of treatment

Alex Bataller

817

Monday, Dec 11
14:45–15:00

Prognostic impact of clonality of myelodysplasia-related gene mutations in AML

Rabea Mecklenbrauck

818

Monday, Dec 11
15:00–15:15

Influence of bone marrow blast enumeration and co-occurring myelodysplasia related gene mutations in NPM1-mutated myeloid malignancies

Curtis A. Lachowiez

821

Monday, Dec 11
15:45–16:00

Molecular and cytogenetic characteristics of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in patients exposed to chemotherapy (CT) and/or radiation (XRT)

Pinkal Desai

837

Monday, Dec 11
15:15–15:30

Genomic profiles and associated survival prognosticators in Black patients with acute myeloid leukemia

Andrew Stiff

957

Monday, Dec 11
17:00–17:15

NPM1-mutated myeloid neoplasms: Updated outcomes with high-intensive chemotherapy regardless of the blast percentage

Georgina Gener-Ricos

959

Monday, Dec 11
17:30–17:45

Clinical and prognostic implications of WT1 mutations in de novo and relapsed acute myeloid leukemia

Himachandana Atluri

2939

Sunday, Dec 10
18:00–20:00

Interaction between presenting features, co-occurring mutations, MRD and induction treatment influences outcome in adults with NPM1 mutated AML – an analysis of 1357 patients in the UK NCRI AML17 and AML19 studies

Jad Othman

LBA-6

Tuesday, Dec 12
09:00–10:30

ERG Is a new predisposition gene for bone marrow failure and hematological malignancy

Hamish S. Scott

63

Saturday, Dec 9 
10:00–10:15

Genomic Characterization of Acute Myeloid Leukemia with Aberrations of Chromosome 7: A Multinational Cohort of 523 Patients

Adriane Halik

217

Saturday, Dec 9
14:00–14:15

Cytokine release syndrome results in reduced AML killing by CD123 CAR T cells

Anand S. Bhagwat

466

Sunday, Dec 10
10:15–10:30

WU-NK-101 (W-NK), a memory-like (ML) NK cell, intrinsically overcomes factors restricting adoptive cell therapy (ACT) in acute myeloid leukemia (AML)

Sergio Rutella

978

Monday, Dec 11
17:45–18:00

Acute myeloid leukemia differentiation state and genotype influence anti-apoptotic protein expression, venetoclax sensitivity, and survival in AML

Curtis A. Lachowiez

165

Saturday, Dec 9
14:30–14:45

Optimizing FLT3 inhibitor use in adult acute myeloid leukemia with FLT3 mutations using proteomics

Eduardo Sabino Magalhaes

290

Saturday, Dec 9
16:15–16:30

CLEC2A is a novel AML-restricted immunotherapeutic target enriched in KMT2A-rearranged acute myeloid leukemia

Danielle Kirkey

423

Sunday, Dec 10
10:00–10:15

Venetoclax has potent efficacy in NPM1 mutated AML with acquired resistance associated with either perturbed pro-survival signalling or NPM1 wild-type populations

Chong Chyn Chua

1577

Saturday, Dec 9
17:30–19:30

Pre-transplant measurable residual disease (MRD) detection of KMT2A-rearranged acute myeloid leukemia is strongly associated with inferior post-transplant outcome

Sun Loo

1588

Saturday, Dec 9
17:30–19:30

Leukemic stem cells (LSCs) as peri-transplant MRD assessment in AML patients undergoing allogeneic stem cell transplantation in CR

Evgeny Klyuchnikov

1591

Saturday, Dec 9
17:30–19:30

Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia

Maria Sirenko

2933

Sunday, Dec 10
18:00–20:00

Single-cell proteomic analysis reveals menin inhibition-induced proteomic alterations in AML patients treated with revumenib

Mahesh Basyal